Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sosei Group ( (JP:4565) ) has issued an announcement.
Nxera Pharma said partner Centessa Pharmaceuticals has reached an early development milestone for ORX489, an orally administered, highly potent and selective orexin receptor 2 agonist being developed for neuropsychiatric disorders. The achievement triggers a US$3 million milestone payment to Nxera, which the company will book as revenue in the first quarter of 2026, underscoring the financial and strategic value of its drug discovery collaborations.
The milestone from Centessa highlights the progress of Nxera’s partnered pipeline alongside its in‑house programs aimed at specialty medicines. This additional non‑dilutive income stream supports Nxera’s growth strategy in its core Japanese and APAC markets and reinforces its positioning as a preferred collaborator in GPCR‑based drug discovery for central nervous system and other specialty indications.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen976.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
More about Sosei Group
Nxera Pharma is a technology‑driven biopharmaceutical company focused on developing specialty medicines for patients with unmet medical needs in Japan and globally. It runs a next‑generation commercial operation in Japan and the broader APAC region and advances an internal and partnered pipeline using its NxWave GPCR structure‑based drug discovery platform, with operations across Japan, the U.K., Switzerland and South Korea.
Average Trading Volume: 852,066
Technical Sentiment Signal: Sell
Current Market Cap: Yen80.09B
Learn more about 4565 stock on TipRanks’ Stock Analysis page.